RARE (Ultragenyx Pharmaceutical Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by RARE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sell | — | — |
| 2026-08-04 | Howard Horn | Chief Financial Officer | Sell | — | — |
| 2026-07-06 | Howard Horn | Chief Financial Officer | Sell | — | — |
| 2026-06-15 | Corazon (Corsee) D. Sanders | Director | Sell | — | — |
| 2026-06-15 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sell | — | — |
| 2026-06-01 | Howard Horn | Chief Financial Officer | Sell | — | — |
| 2026-05-18 | Deborah Dunsire | Director | A | — | — |
| 2026-05-18 | DANIEL G WELCH | Director | A | — | — |
| 2026-05-18 | MICHAEL NARACHI | Director | A | — | — |
| 2026-05-18 | Matthew K Fust | Director | A | — | — |
| 2026-05-18 | Corazon (Corsee) D. Sanders | Director | A | — | — |
| 2026-05-18 | Amrit Ray | Director | A | — | — |
| 2026-05-18 | SHEHNAAZ SULIMAN | Director | MIXED | — | — |
| 2026-05-06 | Eric Crombez | EVP and Chief Medical Officer | Sell | — | — |
| 2026-05-04 | Howard Horn | Chief Financial Officer | Sell | — | — |
| 2026-04-24 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | A | — | — |
| 2026-04-20 | Howard Horn | Chief Financial Officer | A | — | — |
| 2026-04-20 | Eric Crombez | EVP and Chief Medical Officer | A | — | — |
| 2026-04-20 | Erik Harris | EVP & Chief Commercial Officer | A | — | — |
| 2026-04-20 | Karah Herdman Parschauer | EVP and Chief Legal Officer | A | — | — |
| 2026-04-20 | John Richard Pinion | See Remarks | A | — | — |
| 2026-04-20 | Dennis Karl Huang | See Remarks | A | — | — |
| 2026-04-20 | EMIL D KAKKIS | President & CEO | A | — | — |
| 2026-04-02 | Howard Horn | Chief Financial Officer | Sell | — | — |
| 2026-03-10 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sell | — | — |
| 2026-03-03 | Dennis Karl Huang | See Remarks | MIXED | — | — |
| 2026-03-03 | Eric Crombez | EVP and Chief Medical Officer | MIXED | — | — |
| 2026-03-03 | Howard Horn | Chief Financial Officer | MIXED | — | — |
| 2026-03-03 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | MIXED | — | — |
| 2026-03-03 | Karah Herdman Parschauer | EVP and Chief Legal Officer | MIXED | — | — |
| 2026-03-03 | EMIL D KAKKIS | President & CEO | MIXED | — | — |
| 2026-03-03 | Erik Harris | EVP & Chief Commercial Officer | MIXED | — | — |
| 2026-03-03 | John Richard Pinion | See Remarks | MIXED | — | — |
| 2026-02-03 | Howard Horn | Chief Financial Officer | Sell | — | — |
| 2026-01-05 | Howard Horn | Chief Financial Officer | Sell | — | — |
| 2025-12-30 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sell | — | — |
| 2025-12-11 | Howard Horn | Chief Financial Officer | Sell | — | — |
| 2025-10-14 | Howard Horn | Chief Financial Officer | Sell | — | — |
| 2025-09-19 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sell | — | — |
| 2025-09-12 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sell | — | — |
| 2025-09-08 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sell | — | — |
| 2025-06-23 | Corazon (Corsee) D. Sanders | Director | Sell | — | — |
| 2025-05-19 | Amrit Ray | Director | A | — | — |
| 2025-05-19 | Deborah Dunsire | Director | A | — | — |
| 2025-05-19 | Matthew K Fust | Director | A | — | — |
| 2025-05-19 | MICHAEL NARACHI | Director | A | — | — |
| 2025-05-19 | Corazon (Corsee) D. Sanders | Director | A | — | — |
| 2025-05-19 | DANIEL G WELCH | Director | A | — | — |
| 2025-05-19 | SHEHNAAZ SULIMAN | Director | A | — | — |
| 2025-05-05 | Eric Crombez | EVP and Chief Medical Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,085,240 | — |
| — | — | 2,596,420 | — |
| — | 10%+ Owner | 1,457,994 | — |
| — | President & CEO | 935,739 | — |
| — | CBO & EVP | 271,266 | — |
| — | See Remarks | 147,845 | — |
| — | See Remarks | 133,142 | — |
| — | EVP & Chief Commercial Officer | 118,410 | — |
| — | EVP and Chief Medical Officer | 111,189 | — |
| — | EVP, Finance | 97,812 | — |
| — | Chief Financial Officer | 96,295 | — |
| — | EVP and Chief Legal Officer | 92,562 | — |
| — | Director | 77,305 | — |
| — | SVP, Chief Accounting Officer | 68,911 | — |
| — | CFO & Executive Vice President | 66,695 | — |
| — | EVP and Chief Medical Officer | 50,601 | — |
| — | Director | 40,441 | — |
| — | Director | 40,441 | — |
| — | Director | 38,566 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RARE quote page; the site-wide leaderboard is on the insider transactions hub.